Skip to main content
Erschienen in: Medical Oncology 1/2012

01.03.2012 | Original Paper

miR-153 sensitized the K562 cells to As2O3-induced apoptosis

verfasst von: Li Liu, Renan Chen, Siyong Huang, Yanlan Wu, Guohui Li, Bei Zhang, Qiang Liu, Dandan Yin, Yingmin Liang

Erschienen in: Medical Oncology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Relapse remains the biggest hurdle of leukemia therapy, while elucidating the molecular mechanism holds promise for the solution. Recently, microRNAs are emerging as an important regulator of cell function. In this study, we for the first time found that miR-153 was downregulated in As2O3-induced drug-resistant K562 cells. In the CD34+ K562 subpopulation, which is characteristic of leukemia stem cell and resembles the drug-resistant subgroup, miR-153 expression level was also much lower than that in the bulk. Forced expression of miR-153 only in K562 cells has no significant effects on cell growth and apoptosis. However, when cells were additionally treated with As2O3, significant greater apoptosis was observed in the miR-153 overexpressed group. Our data here suggest that strategies increasing the endogenous miR-153 might hold promise for an alternative adjuvant therapy of leukemia.
Literatur
1.
Zurück zum Zitat Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–3.PubMedCrossRef Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–3.PubMedCrossRef
2.
Zurück zum Zitat Holyoake DT. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol. 2001;113:11–23.PubMedCrossRef Holyoake DT. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol. 2001;113:11–23.PubMedCrossRef
3.
4.
Zurück zum Zitat Goldman JM, Melo JV. Chronic myeloid leukemia–advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451–64.PubMedCrossRef Goldman JM, Melo JV. Chronic myeloid leukemia–advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451–64.PubMedCrossRef
5.
Zurück zum Zitat Yin T, Wu YL, Sun HP, Sun GL, Du YZ, Wang KK, Zhang J, Chen GQ, Chen SJ, Chen Z. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004;104:4219–25.PubMedCrossRef Yin T, Wu YL, Sun HP, Sun GL, Du YZ, Wang KK, Zhang J, Chen GQ, Chen SJ, Chen Z. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004;104:4219–25.PubMedCrossRef
6.
Zurück zum Zitat Gu J, Zhu X, Li Y, Dong D, Yao J, Lin C, Huang K, Hu H, Fei J. miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med Oncol. Feb 9 [Epub ahead of print]. Gu J, Zhu X, Li Y, Dong D, Yao J, Lin C, Huang K, Hu H, Fei J. miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med Oncol. Feb 9 [Epub ahead of print].
7.
Zurück zum Zitat Gao SM, Chen C, Wu J, Tan Y, Yu K, Xing CY, Ye A, Yin L, Jiang L. Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide. Biochem Biophys Res Commun. 2010;403:203–8. Gao SM, Chen C, Wu J, Tan Y, Yu K, Xing CY, Ye A, Yin L, Jiang L. Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide. Biochem Biophys Res Commun. 2010;403:203–8.
8.
Zurück zum Zitat Zhang QY, Mao JH, Liu P, Huang QH, Lu J, Xie YY, Weng L, Zhang Y, Chen Q, Chen SJ, Chen Z. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009;106:3378–83.PubMedCrossRef Zhang QY, Mao JH, Liu P, Huang QH, Lu J, Xie YY, Weng L, Zhang Y, Chen Q, Chen SJ, Chen Z. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009;106:3378–83.PubMedCrossRef
9.
Zurück zum Zitat Holtz MS, Forman SJ, Bhatia R. Non proliferating CML CD34 + progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia. 2005;19:1034–41.PubMedCrossRef Holtz MS, Forman SJ, Bhatia R. Non proliferating CML CD34 + progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia. 2005;19:1034–41.PubMedCrossRef
10.
Zurück zum Zitat Bartel DP. Micro RNAs: genomics. biogenes mech funct Cell. 2004;116:281–97. Bartel DP. Micro RNAs: genomics. biogenes mech funct Cell. 2004;116:281–97.
12.
Zurück zum Zitat Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–8.PubMedCrossRef Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–8.PubMedCrossRef
13.
Zurück zum Zitat Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007;104:15805–10.PubMedCrossRef Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007;104:15805–10.PubMedCrossRef
14.
Zurück zum Zitat Xu J, Liao X, Wong C. Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. Int J Cancer. 2009;126:1029–35. Xu J, Liao X, Wong C. Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. Int J Cancer. 2009;126:1029–35.
15.
Zurück zum Zitat Liu L, Chen R, Huang S, Wu Y, Li G, Liu Q, Yin D, Liang Y. Knockdown of SOD1 sensitizes the CD34 + CML cells to imatinib therapy. Med Oncol. 2010 Apr 21 [Epub ahead of print]. Liu L, Chen R, Huang S, Wu Y, Li G, Liu Q, Yin D, Liang Y. Knockdown of SOD1 sensitizes the CD34 + CML cells to imatinib therapy. Med Oncol. 2010 Apr 21 [Epub ahead of print].
16.
Zurück zum Zitat Chen Y, Peng C, Sullivan C, Li D, Li S. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia. 2010;24:1545–54.PubMedCrossRef Chen Y, Peng C, Sullivan C, Li D, Li S. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia. 2010;24:1545–54.PubMedCrossRef
17.
Zurück zum Zitat Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci. 2010;101:1577–81.PubMedCrossRef Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci. 2010;101:1577–81.PubMedCrossRef
18.
Zurück zum Zitat Hochhaus A, Schenk T, Erben P, Ernst T, La Rosee P, Muller MC. Cause and management of therapy resistance. Best Pract Res Clin Haematol. 2009;22:367–79.PubMedCrossRef Hochhaus A, Schenk T, Erben P, Ernst T, La Rosee P, Muller MC. Cause and management of therapy resistance. Best Pract Res Clin Haematol. 2009;22:367–79.PubMedCrossRef
19.
Zurück zum Zitat Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 2006;43:1–67.PubMedCrossRef Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 2006;43:1–67.PubMedCrossRef
Metadaten
Titel
miR-153 sensitized the K562 cells to As2O3-induced apoptosis
verfasst von
Li Liu
Renan Chen
Siyong Huang
Yanlan Wu
Guohui Li
Bei Zhang
Qiang Liu
Dandan Yin
Yingmin Liang
Publikationsdatum
01.03.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9807-6

Weitere Artikel der Ausgabe 1/2012

Medical Oncology 1/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.